NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) Stock Forecast, Price & News $12.73 +0.09 (+0.71%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$12.37▼$13.0050-Day Range$12.64▼$18.4952-Week Range$6.58▼$26.49Volume471,197 shsAverage Volume367,456 shsMarket Capitalization$535.33 millionP/E RatioN/ADividend YieldN/APrice Target$36.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media 4D Molecular Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside184.8% Upside$36.25 Price TargetShort InterestBearish8.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.89) to ($3.10) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 starsMedical Sector934th out of 972 stocksBiological Products, Except Diagnostic Industry149th out of 152 stocks 3.3 Analyst's Opinion Consensus Rating4D Molecular Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.25, 4D Molecular Therapeutics has a forecasted upside of 184.8% from its current price of $12.73.Amount of Analyst Coverage4D Molecular Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.77% of the outstanding shares of 4D Molecular Therapeutics have been sold short.Short Interest Ratio / Days to Cover4D Molecular Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in 4D Molecular Therapeutics has recently increased by 3.36%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend Yield4D Molecular Therapeutics does not currently pay a dividend.Dividend Growth4D Molecular Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FDMT. Previous Next 1.3 News and Social Media Coverage News Sentiment4D Molecular Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for 4D Molecular Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added 4D Molecular Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, 4D Molecular Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of 4D Molecular Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for 4D Molecular Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 4D Molecular Therapeutics is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 4D Molecular Therapeutics is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio4D Molecular Therapeutics has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About 4D Molecular Therapeutics (NASDAQ:FDMT) Stock4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.Read More FDMT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FDMT Stock News HeadlinesSeptember 25, 2023 | msn.com4D Molecular Therapeutics: Some Failures, A Few Key SuccessesSeptember 14, 2023 | finanznachrichten.de4D Molecular Therapeutics, Inc.: 4DMT Appoints Uneek Mehra as Chief Financial and Business OfficerOctober 1, 2023 | Behind the Markets (Ad)6.5 Million Americans Are DESPERATE for This New Drug from One Tiny CompanyDecades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>September 7, 2023 | finance.yahoo.com4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMDSeptember 7, 2023 | finance.yahoo.com4DMT to Participate in Upcoming Investor ConferencesAugust 9, 2023 | finance.yahoo.com4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational HighlightsAugust 9, 2023 | finance.yahoo.comDespite currently being unprofitable, 4D Molecular Therapeutics (NASDAQ:FDMT) has delivered a 59% return to shareholders over 1 yearJuly 31, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About 4D Molecular TherapeuticsOctober 1, 2023 | Behind the Markets (Ad)6.5 Million Americans Are DESPERATE for This New Drug from One Tiny CompanyDecades of pent-up demand for this "first-ever" treatment could give you WINDFALL PROFITS... Click here to learn more >>>July 31, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for 4D Molecular Therapeutics (FDMT)July 29, 2023 | finance.yahoo.com4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023July 17, 2023 | finance.yahoo.com4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability DataJuly 14, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)July 10, 2023 | seekingalpha.com4D Molecular Therapeutics: Pioneering Gene Therapies And An Impressive Fiscal PerformanceJune 9, 2023 | msn.comB of A Securities Maintains 4D Molecular Therapeutics (FDMT) Buy RecommendationJune 8, 2023 | markets.businessinsider.com4D Molecular Therapeutics Stock Is Trading Higher Today - Here's WhyJune 7, 2023 | finance.yahoo.com4DMT Presents Positive Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial in Patients with Cystic Fibrosis at the ECFS 46th Annual MeetingJune 7, 2023 | finance.yahoo.comAndreas Halvorsen's Firm Storms Deeper Into 4D Molecular TherapeuticsJune 3, 2023 | morningstar.com4D Molecular Therapeutics Inc Ordinary SharesMay 24, 2023 | finance.yahoo.com4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual MeetingMay 24, 2023 | markets.businessinsider.com4D Molecular Therapeutics (FDMT) Gets a Buy from BMO CapitalMay 12, 2023 | finance.yahoo.comAndreas Halvorsen's Firm Packs Further Into 4D Molecular TherapeuticsMay 11, 2023 | finance.yahoo.com4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual MeetingMay 10, 2023 | finance.yahoo.com4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational HighlightsMay 9, 2023 | finance.yahoo.com4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 8, 2023 | finance.yahoo.com4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?May 5, 2023 | seekingalpha.com4D Molecular Therapeutics prices $120M share offeringSee More Headlines Receive FDMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FDMT Company Calendar Last Earnings8/09/2023Today9/30/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FDMT CUSIPN/A CIK1650648 Webwww.4dmoleculartherapeutics.com Phone510-505-2680FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$36.25 High Stock Price Forecast$68.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+184.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-107,490,000.00 Net Margins-4,876.01% Pretax Margin-4,876.01% Return on Equity-43.40% Return on Assets-39.13% Debt Debt-to-Equity RatioN/A Current Ratio23.11 Quick Ratio23.11 Sales & Book Value Annual Sales$2.29 million Price / Sales234.28 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book1.78Miscellaneous Outstanding Shares42,053,000Free Float37,553,000Market Cap$535.33 million OptionableNot Optionable Beta2.37 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. John F. Milligan Ph.D. (Age 62)Exec. Chairman Comp: $150kDr. David H. Kirn M.D. (Age 61)Co-Founder, CEO & Director Comp: $920.97kDr. Fariborz Kamal Ph.D. (Age 60)Pres & COO Comp: $678.4kMs. Theresa Janke (Age 48)Co-Founder & Chief of Staff Mr. Uneek Mehra (Age 51)Chief Financial & Bus. Officer Mike ZanoniVP of Investor RelationsDr. Scott P. Bizily J.D. (Age 51)Ph.D., Chief Legal & HR Officer and Corp. Sec. Dr. Robert Y. Kim M.B.A. (Age 62)M.D., Chief Medical Officer Dr. An Song Ph.D.Chief Devel. OfficerMs. Karen S. Carothers (Age 72)Controller More ExecutivesKey CompetitorsAnavex Life SciencesNASDAQ:AVXLAllogene TherapeuticsNASDAQ:ALLOExscientiaNASDAQ:EXAIAlectorNASDAQ:ALECVectivBioNASDAQ:VECTView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 8,788 shares on 8/21/2023Ownership: 0.085%Nuveen Asset Management LLCSold 59,311 shares on 8/16/2023Ownership: 0.231%Citadel Advisors LLCBought 600 shares on 8/15/2023Ownership: 0.000%Royal Bank of CanadaBought 1,479 shares on 8/15/2023Ownership: 0.008%Lazard Asset Management LLCBought 671 shares on 8/15/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions FDMT Stock - Frequently Asked Questions Should I buy or sell 4D Molecular Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FDMT shares. View FDMT analyst ratings or view top-rated stocks. What is 4D Molecular Therapeutics' stock price forecast for 2023? 6 brokers have issued 1 year price targets for 4D Molecular Therapeutics' shares. Their FDMT share price forecasts range from $13.00 to $68.00. On average, they expect the company's share price to reach $36.25 in the next year. This suggests a possible upside of 184.8% from the stock's current price. View analysts price targets for FDMT or view top-rated stocks among Wall Street analysts. How have FDMT shares performed in 2023? 4D Molecular Therapeutics' stock was trading at $22.21 at the start of the year. Since then, FDMT stock has decreased by 42.7% and is now trading at $12.73. View the best growth stocks for 2023 here. When is 4D Molecular Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our FDMT earnings forecast. How were 4D Molecular Therapeutics' earnings last quarter? 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.77) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.77). The company earned $0.24 million during the quarter, compared to analyst estimates of $1.43 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 43.40% and a negative net margin of 4,876.01%. What ETFs hold 4D Molecular Therapeutics' stock? ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). When did 4D Molecular Therapeutics IPO? (FDMT) raised $101 million in an IPO on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager. What is 4D Molecular Therapeutics' stock symbol? 4D Molecular Therapeutics trades on the NASDAQ under the ticker symbol "FDMT." How do I buy shares of 4D Molecular Therapeutics? Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is 4D Molecular Therapeutics' stock price today? One share of FDMT stock can currently be purchased for approximately $12.73. How much money does 4D Molecular Therapeutics make? 4D Molecular Therapeutics (NASDAQ:FDMT) has a market capitalization of $535.33 million and generates $2.29 million in revenue each year. The company earns $-107,490,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. How many employees does 4D Molecular Therapeutics have? The company employs 137 workers across the globe. How can I contact 4D Molecular Therapeutics? The official website for the company is www.4dmoleculartherapeutics.com. The company can be reached via phone at 510-505-2680 or via email at mzanoni@4dmt.com. This page (NASDAQ:FDMT) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.